Novartis Prexige NDA Re-Submission Expected In 2006; TARGET Data Are Clean, Firm Says

Novartis had earlier predicted a lumiracoxib launch in 2005, should FDA accept existing data to satisfy a request for a hip osteoarthritis study. The long-term TARGET study data have been unblinded, and Novartis sees no “surprises” with regard to Prexige’s liver or cardiovascular safety.

More from Archive

More from Pink Sheet

Japan Looks To Build Domestic Capacity In New Modalities

 
• By 

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

GLP-1 Drug Coverage Growing For Obesity In Medicaid, But Only For Diabetes In Medicare

 
• By 

Coverage data from the two programs suggest Medicare beneficiaries may be more disappointed than Medicaid enrollees by the Trump Administration’s decision not to mandate the programs cover obesity drugs.

US FDA Allows Telework For Reviewers As Companies Detail Layoff-Related Problems

 

The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.